Dear ESSKA Members and Friends,
Despite the increasing use of “Orthobiologics (biological substances to treat musculoskeletal injuries), and the consequent increase of related literature, consistent and unequivocal conclusions regarding their efficacy have yet to be established. One of the main reasons stems from the lack of consensus regarding indications and protocols, and in many cases these technologies are used indiscriminately.
It is ESSKA’s view that a common European strategy would aid and support a better understanding of the full benefits of these therapies and establish a structured path to better understand the optimal role and use of orthobiologics. In this scenario, ESSKA is promoting the “Orthobiologics Initiative” (ORBIT), by ESSKA. Through several steps, starting from an internal survey until reaching a consensus on the use of orthobiologics, the initiative could pave the way to further evolutions of these technologies and the identification of alternative financing and reimbursement models to support ongoing patient access and innovation. In particular, the initiative will focus on the use of blood derivatives, such as Platelet Rich Plasma (PRP) and similar, as well as cell-based products, such as BMAC, SVF, Microfat, ACI/MACI.
To be able to identify efficiently the current use of orthobiologics in Europe, we would be grateful if you could give us 5 minutes of your time to indicate your interest in this topic and your direct experience in the clinical practice.
Despite the increasing use of “Orthobiologics (biological substances to treat musculoskeletal injuries), and the consequent increase of related literature, consistent and unequivocal conclusions regarding their efficacy have yet to be established. One of the main reasons stems from the lack of consensus regarding indications and protocols, and in many cases these technologies are used indiscriminately.
It is ESSKA’s view that a common European strategy would aid and support a better understanding of the full benefits of these therapies and establish a structured path to better understand the optimal role and use of orthobiologics. In this scenario, ESSKA is promoting the “Orthobiologics Initiative” (ORBIT), by ESSKA. Through several steps, starting from an internal survey until reaching a consensus on the use of orthobiologics, the initiative could pave the way to further evolutions of these technologies and the identification of alternative financing and reimbursement models to support ongoing patient access and innovation. In particular, the initiative will focus on the use of blood derivatives, such as Platelet Rich Plasma (PRP) and similar, as well as cell-based products, such as BMAC, SVF, Microfat, ACI/MACI.
To be able to identify efficiently the current use of orthobiologics in Europe, we would be grateful if you could give us 5 minutes of your time to indicate your interest in this topic and your direct experience in the clinical practice.